Gyre Therapeutics, Inc.

NASDAQ:GYRE

Biotechnology

Healthcare
$4.34 -0.15%

+$0.00 today

Market cap
$475.02M
Beta
4.92
P/E (TTM)
-88.3
EPS (TTM)
-$0.07
52W Low $5.44High $9.42

Volume 0.47M

Average 0.09M

GYRE EBITDA Margin

EBITDA as a percentage of revenue.

Gyre Therapeutics, Inc.NASDAQ: GYRE

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -38.0%

EBITDA Margin was -38.0% in Q1 FY2026, down 61.5 pp from a year earlier. On a trailing-twelve-month basis it was 2.7%, down 14.2 pp year over year. Over 3 fiscal years it widened by 4.2 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of -24.1% for the fiscal year ending Dec 2026, down from 14.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-38.0%-39.7 pp QoQ
Last fiscal yearDec 2025
14.5%-2.3 pp YoY
LTMMar 2026
2.7%-14.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-61.5 pp-27.6 pp+33.8 pp
1 year-2.3 pp-38.6 pp-36.3 pp
3 years+4.2 pp+48.9 pp+44.6 pp
5 years+8.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
14.5%
Year-over-year change
-2.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How GYRE compares with its peers on the latest reported figures

  • GYRE's LTM Mar 2026 EBITDA Margin of 2.7% is the highest of the 2 companies compared; the peer median is -4567.0%.
  • Its year-over-year change of -14.2 pp is the highest of 2, against a peer median of -3876.5 pp.
  • Over three fiscal years its change of +4.2 pp compares with a peer median of -6672.9 pp.
GYRE Competitors Peer median
EBITDA Margin for GYRE and competitors
Company Period LTM level YoY 3-year change
GYREGyre Therapeutics, Inc.LTM Mar 20262.7% -14.2 pp+4.2 pp
SRZNSurrozen, Inc.LTM Mar 2026-4567.0% -3876.5 pp-6672.9 pp
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024— ——
GALTGalectin Therapeutics Inc.FY2025— ——
PLRXPliant Therapeutics, Inc.FY2025— ——
Peer median (excluding GYRE) -4567.0%-3876.5 pp-6672.9 pp

Competitors are the stored peer set for GYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.34M102.29M113.45M105.76M116.59M
Cost of Revenue7.67M4.79M4.64M3.88M5.42M
Gross Profit(332K)97.5M108.81M101.87M111.17M
Gross Margin-4.5%95.3%95.9%96.3%95.4%
Research & Development64.57M16.69M13.78M12.02M13.7M
Selling, General & Admin18.82M71.61M75.82M73.62M85.98M
Operating Expenses83.39M88.29M176.04M85.71M99.68M
Depreciation & Amortization290K1.13M1.11M1.59M2.52M
EBITDA(87.64M)10.54M20.33M17.82M16.96M
EBITDA Margin-1194.4%10.3%17.9%16.8%14.5%
Operating Income(83.73M)9.2M(67.23M)16.16M11.49M
Operating Margin-1141.0%9.0%-59.3%15.3%9.9%
Interest Income39K726K1.04M1.55M1.75M
Interest Expense00000
Other Income / Expenses(4.21M)209K(9.74M)7.06M2.95M
Income Before Tax(87.93M)9.41M(76.97M)23.22M14.44M
Pre-Tax Margin-1198.3%9.2%-67.8%22.0%12.4%
Income Tax Expense05.1M8.52M5.32M4.56M
Net Income(87.93M)2.3M(92.93M)12.09M5.03M
Net Margin-1198.3%2.3%-81.9%11.4%4.3%
EPS (Basic)(2.87)0.03(1.41)0.140.06
EPS (Diluted)(2.87)0.03(1.41)0.050.02
Weighted Avg Shares30.64M76.74M65.83M85.09M89.34M
Weighted Avg Shares (Diluted)30.64M75.69M65.83M102.29M103.18M

Gyre Therapeutics, Inc.

NASDAQ:GYRE

Intrinsic Alpha fair value

Locked

Current Price

$4.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.